Pricing Log in Create free account

Kailera Therapeutics, Inc. (KLRA) vs SELLAS Life Sciences Group, Inc. (SLS)

Kailera Therapeutics, Inc. and SELLAS Life Sciences Group, Inc. are both Biotechnology companies. Kailera Therapeutics, Inc. and SELLAS Life Sciences Group, Inc. are of similar size ($1.6B and $1.6B). Across the 8 metrics below, SELLAS Life Sciences Group, Inc. leads on 5 and Kailera Therapeutics, Inc. on 3.

Valuation

Metric KLRA SLS Biotechnology median
P/E n/m n/m 10.60
P/S n/m 149.37 9.40
P/B 1.63 11.39 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 136.22 9.02
Earnings yield 661,008,480.09% (2.53%) (32.88%)
Free cash flow yield (19.39%) (2.45%) (23.13%)

Profitability

Metric KLRA SLS Biotechnology median
Gross margin — 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (85.74%) (39.63%) (51.96%)
Return on assets (55.25%) (36.54%) (46.06%)
Return on invested capital (182.92%) 0.00% 0.00%

Growth

Metric KLRA SLS Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) — 50.00% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KLRA SLS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 21.84 18.83 4.97
Net debt to EBITDA 3.46 2.54 1.01

Dividend

Metric KLRA SLS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KLRA SLS Biotechnology median
Market cap 1.58b 1.59b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack